Autolus

The company's core technology revolves around Chimeric Antigen Receptors (CARs), which reprogram a patient's own T-cells to recognize and eliminate cancer cells. Autolus has developed proprietary technologies to create precisely targeted and controlled T-cell therapies. These are designed to overcome the limitations of current treatments by enhancing safety and efficacy. Its manufacturing process includes a proprietary viral vector and a semi-automated method for engineering the patient's T-cells. In 2018, Autolus went public with an Initial Public Offering (IPO) on Nasdaq, raising approximately $150 million.

The company's lead product is obe-cel (obecabtagene autoleucel), also known as AUCATZYL®. Obe-cel is a CAR T-cell therapy targeting CD19, designed with a fast target binding off-rate to reduce toxicity and T-cell exhaustion. This therapy has received FDA approval in the U.S. and conditional marketing authorizations in the U.K. and Europe for the treatment of relapsed or refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) in adults. As of August 2025, the company reported having 46 activated treatment centers in the U.S. and securing coverage for over 90% of U.S. medical lives. The company's revenue is primarily generated from product sales, collaborations, and licensing agreements. For the second quarter of 2025, Autolus reported net product revenue of $20.9 million for AUCATZYL®.

Autolus's pipeline includes treatments for various hematological malignancies and solid tumors. The company is also exploring the potential of obe-cel in treating autoimmune diseases like Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS), with clinical trials underway. Other pipeline candidates include AUTO4 for T-cell lymphoma and AUTO8 for multiple myeloma. The company has engaged in strategic collaborations with entities like Blackstone, Moderna, and the Cell and Gene Therapy Catapult to advance its manufacturing and development capabilities.